← Back to screener

IRADIMED CORP IRMD

Rank #1041 · Nasdaq · $1.0B market cap
Audited by RSM US LLP, no going-concern flag in the latest filing.
Score
54.4
P/E
51.0
P/B
13.72
ROE
26.9%
Op. Margin
30.0%
Debt Ratio
16%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 51.0x, P/B 13.72x. Ranks in the top 68% of the universe.

Profitability ★★★★☆
Excellent

ROE 26.9%. Ranks in the top 12% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 16%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆
Good

Revenue growth of 11.7% year over year. Ranks in the top 31% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014$0.0B$0.0B$0.0B$0.0B24.649
2015$0.0B$0.0B$0.0B$0.0B19.645
2016$0.0B$0.0B$0.0B$0.0B19.661
2017$0.0B$0.0B$0.0B$0.0B36.425
2018$0.0B$0.0B$0.0B$0.0B33.619
2019$0.0B$0.0B$0.0B$0.0B5.620
2020$0.0B$0.0B$0.0B$0.0B19.734
2021$0.0B$0.0B$0.0B$0.0B22.523
2022$0.0B$0.0B$0.0B$0.1B23.517
2023$0.1B$0.0B$0.0B$0.1B29.316
2024$0.1B$0.0B$0.0B$0.1B30.628
2025$0.1B$0.0B$0.0B$0.1B30.016

← See the full screener